BeOne Medicines (formerly BeiGene) sold its worldwide royalty rights outside China for Imdelltra (tarlatamab) sales to Royalty Pharma for an upfront of approximately $885 million, with a total deal value around $950 million. Imdelltra, recently launched for small cell lung cancer, generated $215 million in sales in the first half of 2025. The transaction strengthens BeOne’s financial position amid ongoing R&D investments.